Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ: ALLR )

0.1680 -0.0185 (-9.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,791,629
Open 0.1840
Bid (Size) 0.1688 (21)
Ask (Size) 0.1690 (1)
Prev. Close 0.1865
Today's Range 0.1679 - 0.1849
52wk Range 0.1679 - 69.00
Shares Outstanding 198,742,643
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
From Allarity Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-98.45%
-98.45%
1 Month
-61.93%
-61.93%
3 Month
-89.09%
-89.09%
6 Month
-98.12%
-98.12%
1 Year
-99.72%
-99.72%

More News

Read More
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Why Allarity Therapeutics (ALLR) Stock Is Getting Hammered
Via Benzinga
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
ALLR Stock Earnings: Allarity Therapeutics Reported Results for Q1 2024
Via InvestorPlace
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
From Allarity Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
From Allarity Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?
Via Benzinga
JPMorgan Just Raised Its Price Target on Carvana (CVNA) Stock
Via InvestorPlace
Emergent BioSolutions Layoffs 2024: What to Know About the Latest EBS Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Is Allarity Therapeutics (ALLR) Stock Up 39% Today?
Via InvestorPlace
Nasdaq Jumps Over 100 Points; Kellanova Posts Upbeat Results
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2023 Diversified Communications. All rights reserved.